RNXT vs. CPIX, GDTC, SYBX, BFRG, TXMD, BNTC, SLGL, LSTA, MEIP, and TCRT
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Cumberland Pharmaceuticals (CPIX), CytoMed Therapeutics (GDTC), Synlogic (SYBX), Bullfrog AI (BFRG), TherapeuticsMD (TXMD), Benitec Biopharma (BNTC), Sol-Gel Technologies (SLGL), Lisata Therapeutics (LSTA), MEI Pharma (MEIP), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical preparations" industry.
RenovoRx (NASDAQ:RNXT) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
In the previous week, Cumberland Pharmaceuticals had 23 more articles in the media than RenovoRx. MarketBeat recorded 24 mentions for Cumberland Pharmaceuticals and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.08 indicating that RenovoRx is being referred to more favorably in the media.
RenovoRx has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -15.87%. Cumberland Pharmaceuticals' return on equity of 6.84% beat RenovoRx's return on equity.
RenovoRx currently has a consensus price target of $8.50, indicating a potential upside of 520.44%. Given RenovoRx's higher probable upside, equities analysts plainly believe RenovoRx is more favorable than Cumberland Pharmaceuticals.
3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cumberland Pharmaceuticals received 181 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 45.17% of users gave Cumberland Pharmaceuticals an outperform vote while only 37.50% of users gave RenovoRx an outperform vote.
Cumberland Pharmaceuticals has higher revenue and earnings than RenovoRx. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.
RenovoRx has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500.
Summary
Cumberland Pharmaceuticals beats RenovoRx on 10 of the 16 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
